Key Takeaways
- Custom synthesis pipeline is the quarter's bright spot: RFP and on-site visit activity is rising, multiple Phase III projects are advancing, and GLP-1 peptide work is progressing across several MNC customers, though no revenue timeline is committed.
- Generics grew ~7-8% YoY, but pricing masks the real story: Volumes are up double digits and Divi's holds top-three global share in key products, yet persistent price erosion keeps the revenue line muted.
- Kakinada Phase I is now partly live: Commercial production began in January 2025, with the rest of Phase I expected operational in about 6 months; the backward integration move will free up regulatory-approved capacity at Units 1 and 2.
- Margins have structurally reset lower vs a decade ago: EBITDA margins, once 37-38%, now sit around 31-32% as the "new normal," driven by permanently higher regulatory, GMP, and logistics costs.
- What to watch next quarter: Whether the freed-up Unit 1 and 2 capacity finds quick fill from the pipeline, any tariff actions from the new US administration, and the pace of freight rate normalization after the Middle East ceasefire.
Custom Synthesis: Pipeline & GLP-1
- Engagement is broadening: Management flagged a rise in RFPs and on-site customer visits, with multiple new projects at different stages of the product life cycle, from validation through to customer filings.
- Phase III pipeline is rich but uncommitted: Several opportunities sit in Phase III, some being commercialized, some in validations; management declined to put a timeline on any single project's revenue contribution, citing regulatory dependency.
- GLP-1 capability is deep and differentiated: Divi's manufactures via both SPPS and LPPS, and makes its own resins, building blocks, and protected amino acids, an integration edge management believes competitors lack. A pilot plant is built and has successfully delivered products for customers at various phases.
- Customer interest is broad but timelines are opaque: Over the last six months, Divi's has seen several opportunities and is working closely with most MNCs; management cannot put a timeline on peptide supplies because it depends on each customer's phase, qualification, and regulatory approvals.
- Confidentiality limits disclosure: Management declined to detail the extent of GLP-1 backward integration, specifics of a 500-liter reactor order, or why innovators are not adding capacity in Europe and the US.
Dr. Kiran S. Divi: "We make our own resins. We make our own building blocks. Okay. We make our own protected amino acids. And that's why we have a much more edge over working over others. So I would say in this GLP-1 right now the way things are looking, sky is the limit."
Generic Business: Volume Strength, Price Weakness
- Revenue grew 7-8% YoY, the first growth in some time: The uptick is volume-driven, with new molecules stabilizing, but pricing pressure means the revenue number understates the underlying demand recovery.
- Volume tells a different story: On a volume basis, the generic segment has double-digit growth. Divi's holds the number one, two, or three manufacturer position globally for some products and has not lost business, reduced production, or lost customers.
- Market stabilization is gradual: Management sees markets slowly stabilizing, with demand increasing in several molecules not seen since COVID; destocking effects are slowly fading. No timeline is given for when pricing pressure will ease enough to deliver double-digit revenue growth.
- Portfolio additions are the growth lever: The company anticipates that new generic portfolio additions will play a crucial role as a wave of patent expirations approaches.
Nilima Prasad Divi: "If I'm looking at the volume base, there is double-digit growth. We still hold a substantial market share in some of our products, where we are one of the -- either number one, number two or number three manufacturer in the world. We haven't lost business. We haven't reduced our production. We haven't lost our customers. It's just that because of pricing pressure, the number is not looking great."
Kakinada Unit 3: Phase I Goes Live
- Partial commissioning achieved: Part of Phase I of the Unit 3 facility near Kakinada entered commercial production in January 2025, focused initially on starting materials and registered starting material manufacturing.
- Rest of Phase I on a 6-month clock: Implementation is progressing well and the remainder is expected operational in about 6 months.
- Backward integration unlocks existing capacity: Moving starting materials and some Nutraceutical APIs to Kakinada frees up space at Units 1 and 2, which are already regulatory-approved and can be used for any immediate requirement.
- Capacity fill is the next question: Units 1 and 2 currently run at ~80% utilization; management expects to know better next quarter how pipeline projects will fill the freed-up capacity.
- Phase II and regulatory approvals are open-ended: Management cannot comment on Phase II as of now; some materials manufactured at Kakinada will require regulatory approvals to expand the facility's scope.
Margins & Cost Structure
- Current margins reflect product mix: The Q3 EBITDA margin of ~32% and gross margin of ~60% are a function of the mix between custom synthesis and generics, plus new products; management finds it difficult to predict a sustainable level.
- A structural reset, not a cycle: EBITDA margins were consistently 37-38% a decade ago and now sit around 31%. Management attributes the decline to permanently higher costs: increased regulatory landscape expenses, higher GMP requirements, QC equipment costs (e.g., Nitrosamine impurity testing on every product), and elevated logistics costs from Red Sea disruptions. This is described as the "new normal."
- Logistics costs are easing but not yet normal: Red Sea disruptions and port congestion forced vessels via South Africa, increasing costs and delays; a surge in air cargo demand added strain. With the recent Middle East ceasefire, management is cautiously optimistic that trade routes will shorten and freight rates will normalize as carriers adjust.
- Operational efficiency is a stated priority: Management wants to be operationally more efficient than currently and provide a better outlook, though no quantified target was given.
Dr. Kiran S. Divi: "A lot of things have changed in terms of the regulatory landscape, the cost of regulatory landscape, the cost of GMP requirements for what it was 10 to 15 years ago to what it is now. For a product launch, what used to be the cost to what it is today, it's a complete separate -- we have to look at it like a cost structure itself to understand the product viability and everything."
Contrast Media, Nutraceuticals & Other Verticals
- Contrast media is a conviction bet: Divi's is working with most innovators at different stages, from qualifications to commercial discussions, and believes it will be very strong in Iodine-based contrast media products.
- But the segment split is undisclosed: Management declined to disclose the portion of contrast media revenue coming from custom synthesis vs generics, or whether growth momentum is similar in both spaces, noting only that innovators control the majority share.
- Nutraceuticals are recovering slowly: The division saw a post-COVID demand dip but is now seeing a steady increase; Kakinada Phase I will free up space to increase volumes in several new vitamins. Management expects results in the coming 6 months.
- Oligonucleotides are on the radar: Divi's is looking at multiple products and technologies including oligonucleotides and is active in most segments.
- US tariff risk is acknowledged but unquantified: Management has not yet seen any tariffs for India; if they come, strategic decisions will follow, and the company's European export presence would be an advantage.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Kakinada Phase I completion | Rest of Phase I operational | About 6 months |
| Nutraceutical results visibility | Results from Nutraceutical efforts | Coming 6 months |
| Unit 1 & 2 capacity fill clarity | Pipeline projects filling freed-up capacity | Next quarter |
| Double-digit revenue growth target | Conservative yearly target, not quarter-specific | On a yearly basis |
| Generic vs custom synthesis balance | Wishful thinking to reach 50/50 split | No timeline (ongoing effort) |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Consolidated total income | ₹2,401 cr, vs ₹1,915 cr in Q3 FY24 |
| Profit before tax | ₹726 cr, vs ₹489 cr in Q3 FY24 |
| Profit after tax | ₹589 cr, vs ₹358 cr in Q3 FY24 |
| EBITDA margin | 32%, product-mix driven; no one-off cited |
| Gross margin | 60%, benefited from segmental mix |
| Material consumption | 40% of sales revenue, 9M FY25 |
| Constant currency growth (9M) | 22%, vs negative 10% in 9M FY24 |
| Product mix: generics vs custom synthesis | 47% generics, 53% custom synthesis |
| Nutraceutical revenue | ₹170 cr |
| Exports share | 87% of total sales revenue, 9M FY25 |
| Exports to Europe and U.S. | 72% of total sales revenue, 9M FY25 |
| Forex gain (9M) | ₹38 cr, vs ₹32 cr in 9M FY24 |
| Capacity utilization (Unit 1 and Unit 2) | 80% |
| Kakinada project total spend (till Dec 31, 2024) | ₹1,340 cr, including assets capitalized |
| Capital work in progress | ₹1,157 cr, of which Kakinada is ₹745 cr |
| Cash on books | ₹3,659 cr as of Dec 31, 2024 |
| Effective tax rate guidance | 25%, new regime adopted from FY25 |